KAUNAS, LITHUANIA: Researchers in Lithuania are conducting a groundbreaking study titled "Regular Home-Use of Dual-Light Photodynamic Therapy in Managing Chronic Stage III-IV Periodontitis" (LumoKaunas2023), commenced in August 2023 in Kaunas, to evaluate a novel light-activated antibacterial method for managing advanced periodontitis.
Led by Associate Professor Ingrida Pacauskiené, with support from Prof Vita Mačiulskienė, Dr Renata Šadzevičienė, and dentist Raimonda Guntulytė, the study focuses on the efficacy of the Lumoral device in treating chronic, advanced periodontitis. Of the planned 60 participants, 38 have already been enrolled for the study.
The Lumoral device, developed by Finnish scientists, utilises a specialised mouthwash and antibacterial light therapy for targeted, light-activated treatment.
While earlier studies, such as the HOPE-CP study, demonstrated its effectiveness for early-stage periodontitis, LumoKaunas2023 seeks to determine its potential in managing more severe cases.
Periodontitis, a widespread but serious condition, involves inflammation and damage to the gums and surrounding tissues. Advanced cases can lead to tooth loss and systemic infections. Light-activated therapies like Lumoral offer promising alternatives for managing these risks.
"The LumoKaunas2023 study is examining whether this innovative therapy can effectively address advanced periodontitis," said Mikko Kylmänen, clinical research project manager at Koite Health Oy, during a visit to the Kaunas research team. The trial is being closely monitored by Insuvia UAB to ensure high-quality data and reliable findings.
The HOPE-CP study’s results showed significant benefits of antibacterial light therapy in managing early-stage periodontitis. Participants using Lumoral experienced a 54pc healing rate from gum inflammation, as measured by the BOP (bleeding on probing) index, compared to just 22pc in the control group. Additionally, 67pc of Lumoral users reduced the number of deep gum pockets by half, with some eliminating them entirely.
"The evidence strongly suggests that regularly removing bacteria from dental plaque can significantly improve oral hygiene and treat gum disease," said Lumoral developer and heart surgeon, Tommi Pätilä.
The study is expected to conclude by early autumn 2025, marking a critical step in periodontal care innovation. "We eagerly anticipate more evidence on how the Lumoral device can improve outcomes for patients with severe periodontitis," said Kylmänen.
In addition to improving oral hygiene and reducing infection risks, Lumoral offers a cost-effective, at-home adjunct to professional treatments.
Dr Pätilä highlighted its potential to ease pressure on dental care systems by reducing the reliance on extensive in-clinic procedures.
The study underscores the importance of integrating advanced technologies with routine dental care to enhance patient outcomes and mitigate the impact of periodontal disease on overall health.